Latest Regulatory News

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Caravel Minerals confirms its Definitive Feasibility Study for the Caravel Copper Project remains on track for mid-2026, while regulatory water investigations push the Final Investment Decision to late 2027. Meanwhile, strategic talks with Adani advance steadily.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Elevra Lithium Limited reported an 8% revenue increase and a US$74 million profit for the first half of FY26, driven by higher lithium prices and strategic merger synergies. The company advances its North American Lithium expansion while managing temporary production challenges.

Sea Forest Limited has reported a remarkable 236% increase in SeaFeed revenue for the first half of 2026, surpassing breakeven cattle commitments and securing new international partnerships.

Embark Early Education Limited delivered a robust 2025 financial performance, marked by significant revenue and EBITDA growth, while setting sights on expanding through a strategic takeover bid for Mayfield Childcare Limited.